Physician profile
Bindiya Magoon
NPI 1750576583
$8,014.50
in general payments reported to CMS, 2019-2025
55 companies · $2,171 in 2025
The $2,171 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,092 · 2020: $277 · 2021: $469 · 2022: $619 · 2023: $1,503 · 2024: $1,884 · 2025: $2,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,474 · Gift: $59.40 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,473.91 |
| Gift | $59.40 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,130.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $663.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $531.21 | 2022-2025 | |
| Corcept Therapeutics | $500.75 | 2019-2025 | Korlym |
| Insulet Corporation | $414.79 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $398.93 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Mannkind Corporation | $361.15 | 2022-2025 | Afrezza, V-Go |
| Dexcom, INC. | $353.87 | 2019-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $272.07 | 2019-2025 | Evenity, Prolia, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.90 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $247.69 | 2019-2025 | |
| Radius Health, INC. | $242.52 | 2019-2025 | Tymlos |
| Beta Bionics, INC. | $230.85 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sequel Med Tech, LLC | $180.13 | 2025 | Twiist |
| Merck Sharp & Dohme LLC | $148.76 | 2019-2023 | Steglujan, Steglatro |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $114.79 | 2020-2021 | |
| Recordati_rare_diseases_inc. | $105.74 | 2024-2025 | Isturisa, Signifor Lar |
| Cequr Corporation | $101.92 | 2023-2025 | Cequr Simplicity |
| Amneal Pharmaceuticals LLC | $100.67 | 2020-2024 | Unithroid |
| Medtronic Minimed, INC. | $99.96 | 2019 | |
| Neurocrine Biosciences, INC. | $97.97 | 2024-2025 | |
| Amarin Pharma, INC. | $95.90 | 2020-2021 | |
| Horizon Therapeutics Plc | $94.80 | 2019-2022 | |
| Kyowa Kirin, INC. | $92.78 | 2023-2025 | Crysvita |
| Novartis Pharmaceuticals Corporation | $88.63 | 2023-2025 | |
| Ascendis Pharma Endocrinology INC | $86.86 | 2023-2025 | Yorvipath |
| Abbott Laboratories | $84.30 | 2020-2024 | Proclaim |
| Endo USA, INC. | $77.86 | 2025 | Aveed |
| Zealand Pharma US, INC. | $74.72 | 2020-2021 | |
| Pfizer INC. | $60.05 | 2019-2023 | |
| Medtronic, INC. | $58.13 | 2024-2025 | Inpen Smart Insulin Delivery System |
| Nevro Corp. | $56.67 | 2022-2023 | Senza |
| Tandem Diabetes Care, INC. | $56.48 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lifescan, INC. | $50.46 | 2022-2023 | |
| Ultragenyx Pharmaceutical INC. | $45.29 | 2022-2023 | |
| Antares Pharma, INC. | $45.27 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Shire North American Group INC | $44.75 | 2019 | |
| Alexion Pharmaceuticals, INC. | $41.90 | 2023-2025 | Strensiq |
| Astellas Pharma US INC | $36.55 | 2024 | Veozah |
| Senseonics, Incorporated | $26.00 | 2019 | |
| Gilead Sciences, INC. | $22.10 | 2019 | |
| Ascensia Diabetes Care US INC. | $21.27 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.43 | 2021 | |
| Ibsa Pharma INC. | $19.43 | 2019 | |
| Solventum Corporation | $18.62 | 2024 | V.A.C. Granufoam, V.A.C. Dermatac |
| Esperion Therapeutics, INC. | $17.42 | 2024 | Nexletol |
| Almatica Pharma LLC | $16.24 | 2025 | Teriparatide |
| Ucb, INC. | $15.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.83 | 2019 | |
| Tolmar, INC. | $14.42 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $13.73 | 2025 | Imcivree |
| Valeritas, INC. | $13.15 | 2019 | |
| Abbvie INC. | $13.09 | 2024 | |
| Roche Diabetes Care, INC. | $11.20 | 2019 | |
| Medtronic Vascular, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bindiya Magoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.